Fast Five: Baxter considers Kidney Care sale, Medtronic earns FDA nod for ablation tech

Fast Five Medtech News Podcast

Welcome to the MassDevice Fast Five medtech news podcast, the show that keeps you up-to-date on the latest breakthroughs in medical technology. Here’s what you need to know for today, March 5, 2024. Check out the show notes at MassDevice.com/podcast. The FDA approved Boston Scientific’s Agent drug-coated balloon. Fast Five hosts Chris Newmarker and Sean Whooley explain the significance of this approval and dive into why analysts think it's a major win for Boston Scientific. BD has initiated a new trial for its Vascular Covered Stent. Find out more about what the stent does and why BD thinks it addresses a significant unmet need. Phagenesis reportedly brought in $42 million in funding for its neurostimulation technology. The hosts take a look at what the technology actually is and what the British medtech company plans to do with its latest cash influx. Medtronic picked up FDA clearance for its latest-generation bone tumor ablation technology. Hear all about what sets this technology apart from the competition and from Medtronic's previous bone ablation system. Baxter has a major update on its planned Kidney Care spinoff. The Fast Five hosts break down a bit of a twist in Baxter's separation plans and discuss how it folds into a recent trend across the medtech space.